Relay Therapeutics, Inc. filings document the regulatory record of a clinical-stage precision-medicine company developing small molecule programs for cancer and genetic disease. Form 8-K reports include operating and financial results, Regulation FD clinical updates for zovegalisib, FDA Breakthrough Therapy designation disclosure, material agreements, capital-structure matters, and governance changes.
Proxy materials describe board composition, committee structure, executive compensation, equity awards, shareholder voting matters, and related governance policies. Other filings address amendments to bylaws, including exclusive-forum provisions, and securities disclosures tied to RLAY common stock and its development-stage pipeline.
Relay Therapeutics, Inc. (RLAY) reports that officer Peter Rahmer has filed a Rule 144 notice to sell up to 50,000 shares of common stock through Morgan Stanley Smith Barney LLC. The planned sale has an aggregate market value of $1,028,500, with an approximate sale date of 08/26/2026 on NASDAQ. The shares relate to Restricted Stock Units granted on 01/28/2025 by the issuer. Relay Therapeutics states that 219,141,631 shares of common stock are outstanding. The filing also notes prior 10b5-1 plan sales of 50,000 shares for $954,560 on 06/30/2026.
Relay Therapeutics, Inc. (symbol RLAY) received a Rule 144 notice relating to a proposed sale of its common stock by stockholder SVF Pauling (Cayman) Ltd. The notice covers up to 6,000,000 shares of common stock to be sold through Citigroup Global Markets Inc. on NASDAQ, with a stated aggregate market value of $123,420,000.00. Shares of Relay Therapeutics common stock outstanding were 219,141,631 as of the date referenced in the notice; this is a baseline figure, not the amount being offered. The securities to be sold were originally acquired upon the automatic conversion of Series C Convertible Preferred Stock in connection with Relay Therapeutics’ initial public offering, with the shares fully paid for in December 2018. The proposed sale date referenced is August 25, 2026.
Relay Therapeutics, Inc. (RLAY) reported that President and CEO Sanjiv Patel sold 48,199 shares of common stock on August 17, 2026 in an open-market transaction at a weighted average price of $20.33 per share, effected pursuant to a Rule 10b5-1 trading plan adopted on October 30, 2025. Following this sale, he directly held 567,699 shares of common stock. Additional shares totaling 199,548 and 687,355 are held in separate irrevocable trusts for the benefit of his family members, with an independent trustee; Patel disclaims beneficial ownership of those trust-held securities.
Relay Therapeutics, Inc. (RLAY) reported that its Chief Financial Officer, Thomas Catinazzo, sold 17,717 shares of common stock on August 14, 2026 in an open-market transaction at a weighted average price of $19.74 per share, under a previously adopted Rule 10b5-1 trading plan. After this sale, he directly holds 140,568 shares of Relay Therapeutics common stock, which include 6,538 shares underlying restricted stock units.
Relay Therapeutics, Inc. has a significant shareholder group led by Commodore Capital LP, which, together with Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz, reports beneficial ownership of 12,000,000 shares of common stock. As of June 30, 2026, this represents 5.5% of the outstanding common stock, based on 218,531,200 shares reported as issued and outstanding. The group reports no sole voting or dispositive power over these shares, but shared voting and shared dispositive power over the full 12,000,000 shares. Commodore Capital LP serves as investment manager to Commodore Capital Master LP, and Atkinson and Kramarz, as managing partners, exercise investment discretion with respect to these securities.
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of Common Stock of Relay Therapeutics, Inc. The Master Fund directly holds 14,106,187 shares of Common Stock. Based on 219,141,631 shares outstanding as of July 31, 2026, this represents 6.4% of the class for each Reporting Person. All 14,106,187 shares are reported with shared power to vote and shared power to dispose, and 0 shares are reported with sole voting or dispositive power. Perceptive Advisors acts as investment manager to the Master Fund, and Joseph Edelman, as managing member of Perceptive Advisors, may be deemed to beneficially own the shares held by the Master Fund.
FMR LLC filed an amended Schedule 13G reporting a significant ownership position in Relay Therapeutics, Inc. common stock. FMR LLC and Abigail P. Johnson together report beneficial ownership of 21,270,751.24 shares of common stock (CUSIP 75943R102), representing 10.0% of the class as of July 31, 2026.
FMR LLC has sole voting power over 21,153,779 shares and sole dispositive power over 21,270,751.24 shares, with no shared voting or dispositive power reported. Abigail P. Johnson reports sole dispositive power over the same 21,270,751.24 shares, with no voting power. One or more other persons may receive dividends or sale proceeds, but no such person holds more than five percent of the class.
Relay Therapeutics, Inc. is offering up to $212,978,049 of common stock from time to time under an amended sales agreement with TD Securities (USA) LLC (TD Cowen) as an at-the-market program on The Nasdaq Global Market.
The company previously sold 16,006,569 shares under the original agreement, leaving about $87,021,951 of capacity there. As of June 30, 2026, 218,531,200 shares were outstanding. An illustrative sale of 11,310,570 shares at $18.83 per share would raise $213.0 million and increase net tangible book value from $3.89 to $4.61 per share, implying dilution of $14.22 per share for new investors at that price.
Relay plans to use any proceeds, together with existing cash, to fund research and clinical development of pipeline candidates, working capital, capital expenditures and general corporate purposes. TD Cowen will earn up to a 3.0% commission on gross proceeds and may be deemed an underwriter, with customary indemnification. The company warns that investing involves a high degree of risk and highlights potential dilution and stock price impact from future equity issuances.
Relay Therapeutics increased the size of its at‑the‑market common stock sales program with TD Securities from $250,000,000 to an aggregate offering price of $462,978,049 and filed a new prospectus supplement covering up to $212,978,049 of additional common shares. As of this report, it has sold approximately $162,978,049 of stock under the program, paying TD Cowen a cash commission of up to 3.0% of gross proceeds, with either party able to suspend sales and no obligation to sell any shares.
For the quarter ended June 30, 2026, revenue was $0.4 million, research and development expenses were $76.5 million, general and administrative expenses were $14.7 million, and net loss was $83.7 million, or $0.41 per share. Cash, cash equivalents and investments totaled $910.9 million, including approximately $316 million of gross proceeds from a May 2026 follow‑on offering, and the company expects this balance to fund operations into 2029. Relay highlighted clinical progress for lead asset zovegalisib, including a 44% objective response rate in a triplet breast cancer regimen, 60% volumetric responses at 12 weeks in vascular anomalies, and ongoing/planned Phase 3 trials in second‑ and first‑line HR+/HER2‑ breast cancer.